KDR and gastric cancer: Likewise, Kim et al. employed stomach-derived dECM to bioprint patient-derived gastric cancer organoids (PDOs) with perfusable vasculature, accurately recapitulating the PDO molecular subtype-specific responses to VEGFR2-targeted therapy (Fig. 7B) [150].